



**PRESS RELEASE
FOR IMMEDIATE DISTRIBUTION**

**VALEO PHARMA RECEIVES APPROVAL FROM HEALTH
CANADA FOR THE TRANSFER OF COMMERCIAL RIGHTS TO
AMETOP™**

- Ametop™ commercialization to begin in July 2020
- First of four Valeo products scheduled for launch this summer

MONTREAL, QUEBEC , July 13, 2020 – [Valeo Pharma Inc.](#) (CSE:VPH) (“Valeo” or the “Company”), a Canadian specialty pharmaceutical company, announced today that it has received a Notice of Compliance from Health Canada authorizing the transfer of the Ametop™ commercial rights to Valeo. Valeo entered into a licensing agreement with Alliance Pharma plc in April 2020 for the exclusive commercialization rights to Ametop™ in Canada.

“With Health Canada’s approval, we are ready to commence commercialization of Ametop™ in July ”, said Steve Saviuk, Valeo’s President and CEO. “Ametop is the first of the four products we will be launching this summer. We are also anticipating the approval of Redesca, a low molecular weight heparin, in early fall. These launches and the Redesca approval are key drivers in our move towards profitability.”

About Ametop™ (tetracaine hydrochloride gel)

AMETOP™ Gel is a 4%w/w tetracaine hydrochloride gel indicated for percutaneous local anesthetic to produce anesthesia of the skin prior to venepuncture or venous cannulation, including intravenous injections of medications. AMETOP™ has been commercialized in Canada since 1998.

About Valeo Pharma

Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada with a focus on Neurodegenerative Diseases, Oncology and Hospital Specialty Products. Headquartered in Kirkland, Quebec Valeo Pharma has all the required capabilities and the full infrastructure to register and properly



manage its growing product portfolio through all stages of commercialization. For more information, please visit www.valeopharma.com and follow us on [LinkedIn](#) and [Twitter](#).

Forward Looking Statements

This press release contains forward-looking statements about Valeo's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

For more information:

Valeo Pharma

Steve Saviuk
President and CEO
514 693-8830
saviuk@valeopharma.com

Or

Frederic Dumais
Director Communications and Investor Relations
514-782-8803
dumais@valeopharma.com